AtCor signs $800K contract expansion
AtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Following its recent announcement of a 1H13 profit, AtCor Medical has now added a further $800,000 to its expected revenues following the signing of a contract expansion to an existing customer.
AtCor will supply SphygmoCor to a major pharmaceutical company to support clinical trials in North and South America, Europe and Asia.
SphygmoCor is the company’s device for measuring central aortic blood pressures and arterial stiffness non-invasively.
“We are delighted to have secured this expansion contract,” said AtCor Medical CEO Duncan Ross.
“The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs.”
AtCor (ASX:ACG) was up 1% at 10c in light trading as of around 11 am Monday morning.
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
